Entrada Therapeutics reported a net loss of $17.349 million for the three months ended March 31, 2025, a significant decrease from a net income of $23.496 million in the same period last year. This was primarily due to a decrease in collaboration revenue, which was $20.558 million in Q1 2025 compared to $59.120 million in Q1 2024, largely influenced by a $38.7 million cumulative catch-up adjustment in the prior year. Operating expenses increased to $42.348 million from $38.007 million.

Entrada Therapeutics reported a net income of $1.1 million for Q4 2024, with collaboration revenue reaching $37.4 million. The company's cash, cash equivalents, and marketable securities totaled $420 million, expected to fund operations into Q2 2027.

Entrada Therapeutics reported a net loss of $14.0 million for Q3 2024, compared to a net income of $35.5 million for the same period in 2023. Cash, cash equivalents, and marketable securities were $449.3 million as of September 30, 2024, expected to fund operations into 2027. Collaboration revenue was $19.6 million, and R&D expenses were $31.3 million.

Entrada Therapeutics reported strong second quarter results, highlighted by positive Phase 1 clinical data for ENTR-601-44, a successful $100 million direct offering, and a cash runway extended into 2027. Collaboration revenue increased significantly due to additional VX-670 research activities and a clinical advancement milestone payment.

Entrada Therapeutics reported a net income of $23.5 million for the first quarter of 2024, a significant increase compared to the net loss of $6.7 million for the same period in 2023. The company's cash, cash equivalents, and marketable securities totaled $327.4 million as of March 31, 2024, and they anticipate their cash runway will extend through the second quarter of 2026.